Biovica International AB (publ) (FRA:9II)

Market Cap	11.72M -25.6%
Revenue (ttm)	1.24M +55.9%
Net Income	-6.43M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0300
Previous Close	0.0306
Day's Range	0.0300 - 0.0300
52-Week Range	0.0002 - 0.0402
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2026

About Biovica International AB

Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 25
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9II

Financial Performance

In fiscal year 2026, Biovica International AB's revenue was 13.49 million, an increase of 55.93% compared to the previous year's 8.65 million. Losses were -69.86 million, -20.27% less than in 2025.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error